Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Moxidectin · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| moxidectin | DRUG | - |
Inclusion Criteria * Men or women of non childbearing potential aged 18 to 50 years inclusive at screening. * Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight greater than or equal to 50 kg. Exclusion criteria * Any clinical important deviation from normal limits in physic...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Moxidectin is being studied for the treatment of infection as an infectious disease therapy. It is a small molecule drug in Phase 1 clinical development. The completed trials enrolled healthy volunteers rather than patients with active infection, so its use in treating infection remains investigational.
Pfizer, Inc. is the developer of moxidectin, and the company trades under the ticker PFE. Pfizer sponsored the Phase 1 trials evaluating the drug's excretion into breast milk and the effect of a high-fat meal on its bioavailability and pharmacokinetics.
Moxidectin is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The drug is investigational and has not been approved for the infection indication described in this development program.
Moxidectin has been studied in two completed Phase 1 trials. NCT00751764 evaluated excretion of moxidectin into breast milk in lactating, non-breastfeeding women in the United Kingdom. NCT00736697 evaluated the effect of a high-fat meal on bioavailability and pharmacokinetics of a single dose in France.
The two completed Phase 1 trials of moxidectin enrolled a total of 66 participants. NCT00751764 enrolled 12 lactating, non-breastfeeding women aged 21 years and older, and NCT00736697 enrolled 54 participants aged 18 years and older. Both studies used healthy volunteers.
The moxidectin Phase 1 trials were randomized but not double-blind, and they used an uncontrolled design. NCT00751764 enrolled only female participants in the United Kingdom, while NCT00736697 enrolled participants of any sex in France. Neither trial selected participants based on a biomarker.